Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile

被引:35
作者
Alam, Mohammed Zahidul [1 ]
Wu, Xiaoqian [1 ,2 ]
Mascio, Carmela [3 ]
Chesnel, Laurent [3 ]
Hurdle, Julian G. [1 ,2 ,4 ]
机构
[1] Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA
[2] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Infect & Inflammatory Dis, Houston, TX USA
[3] Merck & Co Inc, Kenilworth, NJ USA
[4] Texas A&M Hlth Sci Ctr, Coll Med, Dept Microbial & Mol Pathogenesis, Bryan, TX USA
关键词
IN-VITRO; INFECTION; METRONIDAZOLE; EPIDEMIOLOGY; MEMBRANE; PHARMACOKINETICS; FIDAXOMICIN; DAPTOMYCIN; VANCOMYCIN; COLITIS;
D O I
10.1128/AAC.01087-15
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Surotomycin (CB-183,315), a cyclic lipopeptide, is in phase 3 clinical development for the treatment of Clostridium difficile infection. We report here the further characterization of the in vitro mode of action of surotomycin, including its activity against growing and nongrowing C. difficile. This was assessed through time-kill kinetics, allowing a determination of the effects on the membrane potential and permeability and macromolecular synthesis in C. difficile. Against representative strains of C. difficile, surotomycin displayed concentration-dependent killing of both logarithmic-phase and stationary-phase cultures at a concentration that was <= 16x the MIC. Exposure resulted in the inhibition of macromolecular synthesis (in DNA, RNA, proteins, and cell wall). At bactericidal concentrations, surotomycin dissipated the membrane potential of C. difficile without changes to the permeability of propidium iodide. These observations are consistent with surotomycin acting as a membrane-active antibiotic, exhibiting rapid bactericidal activities against growing and nongrowing C. difficile.
引用
收藏
页码:5165 / 5170
页数:6
相关论文
共 29 条
[1]
FECAL METRONIDAZOLE CONCENTRATIONS DURING ORAL AND INTRAVENOUS THERAPY FOR ANTIBIOTIC ASSOCIATED COLITIS DUE TO CLOSTRIDIUM-DIFFICILE [J].
BOLTON, RP ;
CULSHAW, MA .
GUT, 1986, 27 (10) :1169-1172
[2]
Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection [J].
Chilton, C. H. ;
Crowther, G. S. ;
Todhunter, S. L. ;
Nicholson, S. ;
Freeman, J. ;
Chesnel, L. ;
Wilcox, M. H. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (09) :2426-2433
[3]
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial [J].
Cornely, Oliver A. ;
Crook, Derrick W. ;
Esposito, Roberto ;
Poirier, Andre ;
Somero, Michael S. ;
Weiss, Karl ;
Sears, Pamela ;
Gorbach, Sherwood .
LANCET INFECTIOUS DISEASES, 2012, 12 (04) :281-289
[4]
Recurrent Clostridium difficile infection treated with home fecal transplantation: A case report [J].
Duke P.S. ;
Fardy J. .
Journal of Medical Case Reports, 8 (1)
[5]
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin [J].
Figueroa, Iris ;
Johnson, Stuart ;
Sambol, Susan P. ;
Goldstein, Ellie J. C. ;
Citron, Diane M. ;
Gerding, Dale N. .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S104-S109
[6]
Metronidazole - A therapeutic review and update [J].
Freeman, CD ;
Klutman, NE ;
Lamp, KC .
DRUGS, 1997, 54 (05) :679-708
[7]
The Changing Epidemiology of Clostridium difficile Infections [J].
Freeman, J. ;
Bauer, M. P. ;
Baines, S. D. ;
Corver, J. ;
Fawley, W. N. ;
Goorhuis, B. ;
Kuijper, E. J. ;
Wilcox, M. H. .
CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (03) :529-+
[8]
Community-acquired Clostridium difficile infection: an increasing public health threat [J].
Gupta, Arjun ;
Khanna, Sahil .
INFECTION AND DRUG RESISTANCE, 2014, 7 :63-72
[9]
Hedge Dennis D, 2008, Ther Clin Risk Manag, V4, P949
[10]
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections [J].
Hurdle, Julian G. ;
O'Neill, Alex J. ;
Chopra, Ian ;
Lee, Richard E. .
NATURE REVIEWS MICROBIOLOGY, 2011, 9 (01) :62-75